Alere fell 3 percent after it sued Abbott to compel it to get all antitrust approvals required to complete its $5.8 billion merger.
Shares of St. Jude Medical could drop to $55 or lower if the Abbott Laboratories' deal falls apart, Muddy Waters' Carson Block said.
Shares of St. Jude Medical briefly fell more than 8 percent Thursday after Muddy Waters Capital announced the firm is short the stock.
"Fast Money Halftime Report" traders Jon Najarian and Pete Najarian discuss unusual activity with FireEye and Abbott.
CNBC's David Faber reports that sources say Alere subpoena related to 44 patient records.
According to CNBC's Bob Pisani, all the companies reporting today were beat by a larger amount than anticipated. Pisani looks at the day's market action.
U.S. sovereign bonds built on this week's gains Wednesday as demand waned for safe haven assets prompted by the Brexit vote.
U.S. stock-index futures rose on Wednesday as investors cheered better-than-expected earnings from Morgan Stanley.
Power Play: Investing amid volatility
Ohio Gov. John Kasich inherited a state with a dismal economy. Here's what he says the United States can learn from Ohio's big turnaround.
Stephanie Link says Abbott Labs' stock is a buy.
Stephanie Link, TIAA Global Asset Management, has one health care stock pick for viewers, and discusses whether it's time to buy into the current market environment.
Jim Cramer rattles off his take on caller favorite stocks, including this popular play on technology.
What's the outcome for currencies if the United Kingdom votes to leave the EU? Michael Binger, Gradient Investments, likes Abbott and Under Armour stocks.
Michael Farr, Farr Miller & Washington, and Kevin Norris, Univest Wealth Management President, discuss their summer market outlooks and give their picks.
The “Halftime Report” experts discuss.
The FMHR traders, and John Spallanzani, GFI Group, debate the trade on pharma stocks after CNBC's Jim Cramer suggests there are positive signs for the sector.
CNBC's David Faber reports on diagnostic test maker Alere saying it rejected Abbott's attempt to terminate a deal.
Most companies are feeling all right about their business, but weak sales growth is making M&A synergies attractive, Roger Altman says.
Some of the names on the move ahead of the open.